Targeting the tumour vasculature: from vessel destruction to promotion
S Guelfi, K Hodivala-Dilke, G Bergers - Nature Reviews Cancer, 2024 - nature.com
As angiogenesis was recognized as a core hallmark of cancer growth and survival, several
strategies have been implemented to target the tumour vasculature. Yet to date, attempts …
strategies have been implemented to target the tumour vasculature. Yet to date, attempts …
Updates on systemic therapy for hepatocellular carcinoma
P Ntellas, I Chau - American Society of Clinical Oncology Educational …, 2024 - ascopubs.org
This review explores the dynamic landscape of hepatocellular carcinoma (HCC) treatment,
emphasizing on recent developments across various stages and therapeutic approaches …
emphasizing on recent developments across various stages and therapeutic approaches …
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
K Wang, YJ **ang, HM Yu, YQ Cheng, ZH Liu, YY Qin… - Nature Medicine, 2024 - nature.com
Hepatocellular carcinoma (HCC), particularly when accompanied by microvascular invasion
(MVI), has a markedly high risk of recurrence after liver resection. Adjuvant immunotherapy …
(MVI), has a markedly high risk of recurrence after liver resection. Adjuvant immunotherapy …
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer
and the third leading cause of cancer mortality worldwide. The development of effective …
and the third leading cause of cancer mortality worldwide. The development of effective …
Immunotherapy at all stages of hepatocellular carcinoma
A flurry of emerging treatment options is transforming the therapeutic landscape of
hepatocellular carcinoma; two new studies highlight the complexities and gaps in …
hepatocellular carcinoma; two new studies highlight the complexities and gaps in …
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
Abstract In Asia–Pacific region, hepatocellular carcinoma is a serious health threat
attributing to over 600,000 deaths each year and account for over 70% of global cases …
attributing to over 600,000 deaths each year and account for over 70% of global cases …
Tumor microenvironment composition and related therapy in hepatocellular carcinoma
Z Li, Z Zhang, L Fang, J Zhao, Z Niu… - Journal of …, 2023 - Taylor & Francis
Globally, primary liver cancer is the third leading cause of cancer death, and hepatocellular
carcinoma (HCC) accounts for 75%–95%. The tumor microenvironment (TME), composed of …
carcinoma (HCC) accounts for 75%–95%. The tumor microenvironment (TME), composed of …
[HTML][HTML] The treatment of hepatocellular carcinoma with major vascular invasion
T Tadokoro, J Tani, A Morishita, K Fujita, T Masaki… - Cancers, 2024 - mdpi.com
Simple Summary Hepatocellular carcinoma with vascular invasion has a poor prognosis
and inconsistent treatment evidence. Studies of portal vein tumor thrombus are relatively …
and inconsistent treatment evidence. Studies of portal vein tumor thrombus are relatively …
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection
C Fuster-Anglada, E Mauro, J Ferrer-Fàbrega… - Journal of …, 2024 - Elsevier
Background & Aims Assessment of recurrence risk after liver resection (LR) is critical in
hepatocellular carcinoma (HCC), particularly with the advent of effective adjuvant therapy …
hepatocellular carcinoma (HCC), particularly with the advent of effective adjuvant therapy …
Merits and boundaries of the Barcelona Clinic Liver Cancer Staging and Treatment Algorithm: learning from the past to improve the future with a novel proposal.
Summary This Expert Opinion article thoroughly analyses the Barcelona Clinic Liver Cancer
(BCLC) staging and treatment algorithm for hepatocellular carcinoma (HCC) that, since …
(BCLC) staging and treatment algorithm for hepatocellular carcinoma (HCC) that, since …